Flex Pharma (FLKS) Tops Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Flex Pharma (FLKS) PT Lowered to $9 at Jefferies Following 4Q
March 9, 2017 7:37 AM ESTJefferies lowered its price target on Flex Pharma (NASDAQ: FLKS) to $9.00 (from $11.00) while maintaining a Buy rating. FLKS reported EPS and HotShot sales of -$0.48 vs. -$0.62 estimate and $0.3M vs. $0.2M, respectively, with slightly lower opex of $8.3M vs. $10.6M... More
